Sage Journals: Discover world-class research

Abstract

Objective:

We offer an overview of ADHD research using mouse models of nicotine exposure.

Method:

Nicotine exposure of C57BL/6 or Swiss Webster mice occurred during prenatal period only or during the prenatal and the pre-weaning periods. Behavioral, neuroanatomical and neurotransmitter assays were used to investigate neurobiological mechanisms of ADHD and discover candidate ADHD medications.

Results:

Our studies show that norbinaltorphimine, a selective kappa opioid receptor antagonist is a candidate novel non-stimulant ADHD treatment and that a combination of methylphenidate and naltrexone has abuse deterrent potential with therapeutic benefits for ADHD. Other studies showed transgenerational transmission of ADHD-associated behavioral traits and demonstrated that interactions between untreated ADHD and repeated mild traumatic brain injury produced behavioral traits not associated with either condition alone.

Conclusion:

Preclinical models contribute to novel insights into ADHD neurobiology and are valuable tools for drug discovery and translation to benefit humans with ADHD.

Keywords

Norbinaltorphimine naltrexone traumatic brain injury transgenerational transmission abuse deterrent formulation

Get full access to this article

View all access options for this article.

References

Adams

E. K.

Markowitz

Dietz

P. M.

Tong

V. T.

(2013). Expansion of Medicaid covered smoking cessation services: Maternal smoking and birth outcomes. Medicare & Medicaid Research Review, 3(3), mmrr.003.03.a02.

Adeyemo

B. O.

Biederman

Zafonte

Kagan

Spencer

T. J.

Uchida

Kenworthy

Spencer

A. E.

Faraone

S. V.

(2014). Mild traumatic brain injury and ADHD: A systematic review of the literature and meta-analysis. Journal of Attention Disorders, 18(7), 576–584.

Alkam

Kim

H. C.

Hiramatsu

Mamiya

Aoyama

Nitta

Yamada

Nabeshima

(2013). Evaluation of emotional behaviors in young offspring of C57BL/6J mice after gestational and/or perinatal exposure to nicotine in six different time-windows. Behavioural Brain Research, 239, 80–89.

Alkam

Kim

H. C.

Mamiya

Yamada

Hiramatsu

Nabeshima

(2013). Evaluation of cognitive behaviors in young offspring of C57BL/6J mice after gestational nicotine exposure during different time-windows. Psychopharmacology, 230(3), 451–463.

Alosco

M. L.

Fedor

A. F.

Gunstad

(2014). Attention deficit hyperactivity disorder as a risk factor for concussions in NCAA division-I athletes. Brain Injury, 28(4), 472–474.

Altink

M. E.

Slaats-Willemse

D. I.

Rommelse

N. N.

Buschgens

C. J.

Fliers

E. A.

Arias-Vásquez

Franke

Sergeant

J. A.

Faraone

S. V.

Buitelaar

J. K.

(2009). Effects of maternal and paternal smoking on attentional control in children with and without ADHD. European Child & Adolescent Psychiatry, 18(8), 465–475.

Arnsten

A. F.

(2006). Fundamentals of attention-deficit/hyperactivity disorder: Circuits and pathways. The Journal of Clinical Psychiatry, 67(Suppl 8), 7–12.

Arnsten

A. F.

Jin

L. E.

(2012). Guanfacine for the treatment of cognitive disorders: A century of discoveries at Yale. The Yale Journal of Biology and Medicine, 85(1), 45–58.

Balcioglu

Ren

J. Q.

McCarthy

Spencer

T. J.

Biederman

Bhide

P. G.

(2009). Plasma and brain concentrations of oral therapeutic doses of methylphenidate and their impact on brain monoamine content in mice. Neuropharmacology, 57(7-8), 687–693.

10.

Bell

A. M.

Hellmann

J. K.

(2019). An integrative framework for understanding the mechanisms and multigenerational consequences of transgenerational plasticity. Annual Review of Ecology Evolution and Systematics, 50, 97–118.

11.

Benowitz

N. L.

Bernert

J. T.

Caraballo

R. S.

Holiday

D. B.

Wang

(2009). Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. American Journal of Epidemiology, 169(2), 236–248.

12.

Berger

Rothmaier

A. K.

Wedekind

Zentner

Feuerstein

T. J.

Jackisch

(2006). Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex. British Journal of Pharmacology, 148(6), 795–806.

13.

Bhide

P. G.

Zhu

Spencer

T. J.

Biederman

(2021). Methods and compositions to prevent addiction. In USPTO (Ed.), USPTO (Vol. US 11,045,465 B2, pp. 36). Florida State University Research Foundation, The General Hospital Corporation.

14.

Biederman

Feinberg

Chan

Adeyemo

B. O.

Woodworth

K. Y.

Panis

McGrath

Bhatnagar

Spencer

T. J.

Uchida

Kenworthy

Grossman

Zafonte

Faraone

S. V.

(2015). Mild traumatic brain injury and attention-deficit hyperactivity disorder in young student athletes. The Journal of Nervous and Mental Disease, 203(11), 813–819.

15.

Biederman

Fitzgerald

Spencer

T. J.

Bhide

P. G.

McCarthy

D. M.

Woodworth

K. Y.

Saunders

Faraone

S. V.

(2020). Is paternal smoking at conception a risk for ADHD? A controlled study in youth with and without ADHD. Journal of Attention Disorders, 24(11), 1493–1496.

16.

Biederman

Melmed

R. D.

Patel

McBurnett

Donahue

Lyne

(2008). Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectrums, 13(12), 1047–1055.

17.

Biederman

Petty

C. R.

Bhide

P. G.

Woodworth

K. Y.

Faraone

(2012). Does exposure to maternal smoking during pregnancy affect the clinical features of ADHD? Results from a controlled study. The World Journal of Biological Psychiatry, 13(1), 60–64.

18.

Bohacek

Mansuy

I. M.

(2015). Molecular insights into transgenerational non-genetic inheritance of acquired behaviours. Nature Reviews. Genetics, 16(11), 641–652.

19.

Bright

G. M.

(2008). Abuse of medications employed for the treatment of ADHD: Results from a large-scale community survey. Medscape Journal of Medicine, 10(5), 111.

20.

Brown

R. T.

Amler

R. W.

Freeman

W. S.

Perrin

J. M.

Stein

M. T.

Feldman

H. M.

Pierce

Wolraich

M. L.

(2005). Treatment of attention-deficit/hyperactivity disorder: Overview of the evidence. Pediatrics, 115(6), e749–e757.

21.

Bruchas

M. R.

Yang

Schreiber

Defino

Kwan

S. C.

Chavkin

(2007). Long-acting kappa opioid antagonists disrupt receptor signaling and produce noncompetitive effects by activating c-Jun N-terminal kinase. The Journal of Biological Chemistry, 282(41), 29803–29811.

22.

Buck

J. M.

Sanders

K. N.

Wageman

C. R.

Knopik

V. S.

Stitzel

J. A.

O’Neill

H. C

. (2019). Developmental nicotine exposure precipitates multigenerational maternal transmission of nicotine preference and ADHD-like behavioral, rhythmometric, neuropharmacological, and epigenetic anomalies in adolescent mice. Neuropharmacology, 149, 66–82.

23.

Butler

S. F.

Faraone

S. V.

Rostain

A. L.

Newcorn

J. H.

Antshel

K. M.

Robbins

R. S.

Green

J. L.

(2021). Non-medical use of prescription stimulants among college students: Non-oral routes of administration, risk factors, motivations, and pathways. Frontiers in Psychiatry, 12, 667118.

24.

Centner

A. M.

Bhide

P. G.

Salazar

(2020). Nicotine in senescence and atherosclerosis. Cells, 9(4), 1035.

25.

Ciccarone

(2011). Stimulant abuse: Pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Primary Care, 38(1), 41–58.

26.

Clancy

Finlay

B. L.

Darlington

R. B.

Anand

K. J.

(2007). Extrapolating brain development from experimental species to humans. Neurotoxicology, 28, 931–937.

27.

Clancy

Kersh

Hyde

Darlington

R. B.

Anand

K. J.

Finlay

B. L.

(2007). Web-based method for translating neurodevelopment from laboratory species to humans. Neuroinformatics, 5, 79–94.

28.

Cook

N. E.

Iaccarino

M. A.

Karr

J. E.

Iverson

G. L.

(2020). Attention-deficit/hyperactivity disorder and outcome after concussion: A systematic review. Journal of Developmental and Behavioral Pediatrics, 41(7), 571–582.

29.

Cornelius

M. D.

Day

N. L.

(2009). Developmental consequences of prenatal tobacco exposure. Current Opinion in Neurology, 22(2), 121–125.

30.

DePaoli

A. M.

Hurley

K. M.

Yasada

Reisine

Bell

(1994). Distribution of κ opioid receptor mRNA in adult mouse brain: An in situ hybridization histochemistry study. Molecular and Cellular Neurosciences, 5(4), 327–335.

31.

Donelan

S. C.

Hellmann

J. K.

Bell

A. M.

Luttbeg

Orrock

J. L.

Sheriff

M. J.

Sih

(2020). Transgenerational plasticity in human-altered environments. Trends in Ecology & Evolution, 35(2), 115–124.

32.

Faraone

S. V.

Banaschewski

Coghill

Zheng

Biederman

Bellgrove

M. A.

Newcorn

J. H.

Gignac

Al Saud

N. M.

Manor

Rohde

L. A.

Yang

Cortese

Almagor

Stein

M. A.

Albatti

T. H.

Aljoudi

H. F.

Alqahtani

M. M. J.

Asherson

. . . Wang

(2021). The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 128, 789–818.

33.

Faraone

S. V.

Biederman

Mick

(2006). The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. Psychologie Medicale, 36(2), 159–165.

34.

Faraone

S. V.

Biederman

Spencer

Mick

Murray

Petty

Adamson

J. J.

Monuteaux

M. C.

(2006). Diagnosing adult attention deficit hyperactivity disorder: Are late onset and subthreshold diagnoses valid? American Journal of Psychiatry, 163(10), 1720–1729.

35.

Faraone

S. V.

Childress

Caras

Arnold

V. K.

Montano

C. B.

Sarkis

E. H.

Cutler

A. J.

Young

J. L.

(2021). A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AR19, a manipulation-resistant formulation of amphetamine sulfate, in adults with attention-deficit/hyperactivity disorder. The Journal of Clinical Psychiatry, 82(5), 21m13927.

36.

Froggatt

Reissland

Covey

(2020). The effects of prenatal cigarette and e-cigarette exposure on infant neurobehaviour: A comparison to a control group. EClinicalMedicine, 28, 100602.

37.

Fuentealba

J. A.

Gysling

Magendzo

Andrés

M. E.

(2006). Repeated administration of the selective kappa-opioid receptor agonist U-69593 increases stimulated dopamine extracellular levels in the rat nucleus accumbens. Journal of Neuroscience Research, 84(2), 450–459.

38.

Georges

Normand

Bloch

Le Moine

(1998). Opioid receptor gene expression in the rat brain during ontogeny, with special reference to the mesostriatal system: An in situ hybridization study. Brain Research Developmental Brain Research, 109(2), 187–199.

39.

Goldberg

L. R.

Gould

T. J.

(2019). Multigenerational and transgenerational effects of paternal exposure to drugs of abuse on behavioral and neural function. The European Journal of Neuroscience, 50(3), 2453–2466.

40.

Golding

Ellis

Gregory

Birmingham

Iles-Caven

Rai

Pembrey

(2017). Grand-maternal smoking in pregnancy and grandchild’s autistic traits and diagnosed autism. Scientific Reports, 7, 46179.

41.

Golding

van Den Berg

Northstone

Suderman

Ellis

Iles-Caven

Gregory

Pembrey

(2020). Grandchild’s IQ is associated with grandparental environments prior to the birth of the parents. Wellcome Open Research, 5, 198.

42.

Hawkey

A. B.

White

Pippen

Greengrove

Rezvani

A. H.

Murphy

S. K.

Levin

E. D.

(2019). Paternal nicotine exposure in rats produces long-lasting neurobehavioral effects in the offspring. Neurotoxicology and Teratology, 74, 106808.

43.

Huntley

Maltezos

Williams

Morinan

Hammon

Ball

Marshall

E. J.

Keaney

Young

Bolton

Glaser

Howe-Forbes

Kuntsi

Xenitidis

Murphy

Asherson

P. J.

(2012). Rates of undiagnosed attention deficit hyperactivity disorder in London drug and alcohol detoxification units. BMC Psychiatry, 12, 223.

44.

Iverson

G. L.

Atkins

J. E.

Zafonte

Berkner

P. D.

(2016). Concussion history in adolescent athletes with attention-deficit hyperactivity disorder. Journal of Neurotrauma, 33(23), 2077–2080.

45.

Iverson

G. L.

Jones

P. J.

Karr

J. E.

Maxwell

Zafonte

Berkner

P. D.

McNally

R. J.

(2020). Network structure of physical, cognitive, and emotional symptoms at preseason baseline in student athletes with attention-Deficit/ hyperactivity disorder. Archives of Clinical Neuropsychology, 35, 1109–1122.

46.

Jayaram-Lindström

Konstenius

Eksborg

Beck

Hammarberg

Franck

(2008). Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology, 33(8), 1856–1863.

47.

Jayaram-Lindström

Wennberg

Hurd

Y. L.

Franck

(2004). Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. Journal of Clinical Psychopharmacology, 24(6), 665–669.

48.

Joya

Manzano

Álvarez

A. T.

Mercadal

Torres

Salat-Batlle

Garcia-Algar

(2014). Transgenerational exposure to environmental tobacco smoke. International Journal of Environmental Research and Public Health, 11(7), 7261–7274.

49.

Kandra

K. L.

Ranney

L. M.

Lee

J. G.

Goldstein

A. O.

(2014). Physicians’ attitudes and use of e-cigarettes as cessation devices, North Carolina, 2013. PLoS One, 9(7), e103462.

50.

Kantak

K. M.

(2022). Rodent models of attention-deficit hyperactivity disorder: An updated framework for model validation and therapeutic drug discovery. Pharmacology, Biochemistry, and Behavior, 216, 173378.

51.

Kapaya

D’Angelo

D. V.

Tong

V. T.

England

Ruffo

Cox

Warner

Bombard

Guthrie

Lampkins

King

B. A.

(2019). Use of electronic vapor products before, during, and after pregnancy among women with a recent live birth - Oklahoma and Texas, 2015. MMWR. Morbidity and Mortality Weekly Report, 68(8), 189–194.

52.

Kaye

Sundman

M. H.

Hall

E. E.

Williams

Patel

Ketcham

C. J.

(2019). Baseline neurocognitive performance and symptoms in those with attention deficit hyperactivity disorders and history of concussion with previous loss of consciousness. Frontiers in Neurology, 10, 396.

53.

Kollins

S. H.

MacDonald

E. K.

Rush

C. R.

(2001). Assessing the abuse potential of methylphenidate in nonhuman and human subjects: A review. Pharmacology, Biochemistry, and Behavior, 68(3), 611–627.

54.

Kuczenski

Segal

D. S.

(2001). Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: Relative roles of dopamine and norepinephrine. The Journal of Pharmacology and Experimental Therapeutics, 296(3), 876–883.

55.

Kuczenski

Segal

D. S.

(2005). Stimulant actions in rodents: Implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biological Psychiatry, 57(11), 1391–1396.

56.

Liu-Chen

L. Y.

(2004). Agonist-induced regulation and trafficking of kappa opioid receptors. Life Sciences, 75(5), 511–536.

57.

Liu

Doherty

T. M.

Akbari

Allard

Rehan

V. K.

(2020). Perinatal nicotine exposure-induced transgenerational asthma: Effects of reexposure in F1 gestation. The FASEB Journal, 34(9), 11444–11459.

58.

Makris

Biederman

Monuteaux

M. C.

Seidman

L. J.

(2009). Towards conceptualizing a neural systems-based anatomy of attention-deficit/hyperactivity disorder. Developmental Neuroscience, 31(1–2), 36–49.

59.

Makris

Liang

Biederman

Valera

E. M.

Brown

A. B.

Petty

Spencer

T. J.

Faraone

S. V.

Seidman

L. J.

(2015). Toward defining the neural substrates of ADHD: A controlled structural MRI study in medication-naïve adults. Journal of Attention Disorders, 19(11), 944–953.

60.

Margolis

E. B.

Lock

Chefer

V. I.

Shippenberg

T. S.

Hjelmstad

G. O.

Fields

H. L.

(2006). κ opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proceedings of the National Academy of Sciences of the United States of America, 103(8), 2938–2942.

61.

Mark

K. S.

Farquhar

Chisolm

M. S.

Coleman-Cowger

V. H.

Terplan

(2015). Knowledge, attitudes, and practice of electronic cigarette use among pregnant women. Journal of Addiction Medicine, 9(4), 266–272.

62.

Martin

M. M.

McCarthy

D. M.

Schatschneider

Trupiano

M. X.

Jones

S. K.

Kalluri

Bhide

P. G.

(2020). Effects of developmental nicotine exposure on frontal cortical GABA-to-non-GABA neuron ratio and novelty-seeking behavior. Cerebral Cortex, 30, 1830–1842.

63.

Martin

W. R.

Sloan

J. W.

Sapira

J. D.

Jasinski

D. R.

(1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clinical Pharmacology and Therapeutics, 12(2), 245–258.

64.

Maurer

J. J.

Wimmer

M. E.

Turner

C. A.

Herman

R. J.

Zhang

Ragnini

Ferrante

Kimmey

B. A.

Crist

R. C.

Christopher Pierce

Schmidt

H. D.

(2022). Paternal nicotine taking elicits heritable sex-specific phenotypes that are mediated by hippocampal satb2. Molecular Psychiatry, 27, 3864–3874.

65.

McCabe

S. E.

Figueroa

McCabe

V. V.

Schepis

T. S.

Schulenberg

J. E.

Veliz

P. T.

Werner

K. S.

Wilens

T. E.

(2023). Is age of onset and duration of stimulant therapy for ADHD associated with cocaine, methamphetamine, and prescription stimulant misuse? Journal of Child Psychology and Psychiatry, and Allied Disciplines, Advance online publication. https://doi.org/10.1111/jcpp.13807

66.

McCarthy

D. M.

Bhide

P. G.

(2012). Prenatal cocaine exposure decreases parvalbumin-immunoreactive neurons and GABA-to-projection neuron ratio in the medial prefrontal cortex. Developmental Neuroscience, 34(2-3), 174–183.

67.

McCarthy

D. M.

Bhide

P. G.

(2021). Heritable consequences of paternal nicotine exposure: From phenomena to mechanisms. Biology of Reproduction, 105(3), 632–643.

68.

McCarthy

D. M.

Morgan

T. J.

Jr Lowe

S. E

Williamson

M. J

Spencer

T. J

Biederman

Bhide

P. G.

(2018). Nicotine exposure of male mice produces behavioral impairment in multiple generations of descendants. PLoS Biology, 16(10), e2006497.

69.

McCarthy

D. M.

Zhang

Wilkes

B. J.

Vaillancourt

D. E.

Biederman

Bhide

P. G.

(2022). Nicotine and the developing brain: Insights from preclinical models. Pharmacology, Biochemistry, and Behavior, 214, 173355.

70.

McCarthy

D. M.

Zhang

Darnell

S. B.

Sangrey

G. R.

Yanagawa

Sadri-Vakili

Bhide

P. G.

(2011). Cocaine alters BDNF expression and neuronal migration in the embryonic mouse forebrain. The Journal of Neuroscience, 31(38), 13400–13411.

71.

Melief

E. J.

Miyatake

Carroll

F. I.

Béguin

Carlezon

W. A.

Jr Cohen

B. M

Grimwood

Mitch

C. H

Rorick-Kehn

Chavkin

(2011). Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Molecular Pharmacology, 80(5), 920–929.

72.

Milberger

Biederman

Faraone

S. V.

Chen

Jones

(1996). Is maternal smoking during pregnancy a risk factor for attention deficit hyperactivity disorder in children? American Journal of Psychiatry, 153(9), 1138–1142.

73.

Nilsen

F. M.

Tulve

N. S.

(2020). A systematic review and meta-analysis examining the interrelationships between chemical and non-chemical stressors and inherent characteristics in children with ADHD. Environmental Research, 180, 108884.

74.

Nilsson

E. E.

Sadler-Riggleman

Skinner

M. K.

(2018). Environmentally induced epigenetic transgenerational inheritance of disease. Environmental Epigenetics, 4(2), dvy016.

75.

Parasrampuria

D. A.

Schoedel

K. A.

Schuller

Ciccone

Silber

S. A.

Sellers

E. M.

(2007). Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. Journal of Clinical Pharmacology, 47(12), 1476–1488.

76.

Patrick

K. S.

Markowitz

J. S.

(1997). Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Human Psychopharmacology, 12(6), 527–546.

77.

Pauly

J. R.

Slotkin

T. A.

(2008). Maternal tobacco smoking, nicotine replacement and neurobehavioural development. Acta Paediatrica, 97(10), 1331–1337.

78.

Pauly

J. R.

Sparks

J. A.

Hauser

K. F.

Pauly

T. H.

(2004). In utero nicotine exposure causes persistent, gender-dependant changes in locomotor activity and sensitivity to nicotine in C57Bl/6 mice. International Journal of Developmental Neuroscience, 22(5-6), 329–337.

79.

Polli

F. S.

Kohlmeier

K. A.

(2020). Prenatal nicotine exposure in rodents: Why are there so many variations in behavioral outcomes? Nicotine & Tobacco Research, 22(10), 1694–1710.

80.

Rasmussen

Levander

(2009). Untreated ADHD in adults: Are there sex differences in symptoms, comorbidity, and impairment? Journal of Attention Disorders, 12(4), 353–360.

81.

Regan

S. L.

Williams

M. T.

Vorhees

C. V.

(2022). Review of rodent models of attention deficit hyperactivity disorder. Neuroscience and Biobehavioral Reviews, 132, 621–637.

82.

Renaud

S. M.

Fountain

S. B.

(2016). Transgenerational effects of adolescent nicotine exposure in rats: Evidence for cognitive deficits in adult female offspring. Neurotoxicology and Teratology, 56, 47–54.

83.

Russell

V. A.

Sagvolden

Johansen

E. B.

(2005). Animal models of attention-deficit hyperactivity disorder. Behavioral and Brain Functions: BBF, 1(1), 9.

84.

Sagvolden

Johansen

E. B.

(2012). Rat models of ADHD. Current Topics in Behavioral Neurosciences, 9, 301–315.

85.

Schiffer

W. K.

Volkow

N. D.

Fowler

J. S.

Alexoff

D. L.

Logan

Dewey

S. L.

(2006). Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse, 59(4), 243–251.

86.

Schneider

Ilott

Brolese

Bizarro

Asherson

P. J.

Stolerman

I. P.

(2011). Prenatal exposure to nicotine impairs performance of the 5-Choice serial reaction time task in adult rats. Neuropsychopharmacology, 36(5), 1114–1125.

87.

Seidman

L. J.

Biederman

Liang

Valera

E. M.

Monuteaux

M. C.

Brown

Kaiser

Spencer

Faraone

S. V.

Makris

(2011). Gray matter alterations in adults with attention-deficit/hyperactivity disorder identified by voxel based morphometry. Biological Psychiatry, 69(9), 857–866.

88.

Seidman

L. J.

Valera

E. M.

Makris

Monuteaux

M. C.

Boriel

D. L.

Kelkar

Kennedy

D. N.

Caviness

V. S.

Bush

Aleardi

Faraone

S. V.

Biederman

(2006). Dorsolateral prefrontal and anterior cingulate cortex volumetric abnormalities in adults with attention-deficit/hyperactivity disorder identified by magnetic resonance imaging. Biological Psychiatry, 60(10), 1071–1080.

89.

Semple

B. D.

Blomgren

Gimlin

Ferriero

D. M.

Noble-Haeusslein

L. J.

(2013). Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species. Progress in Neurobiology, 106-107, 1–16.

90.

Shaw

Hodgkins

Caci

Young

Kahle

Woods

A. G.

Arnold

L. E.

(2012). A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: Effects of treatment and non-treatment. BMC Medicine, 10, 99.

91.

Shaw

Lerch

Greenstein

Sharp

Clasen

Evans

Giedd

Castellanos

F. X.

Rapoport

(2006). Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 63(5), 540–549.

92.

Simonin

Gavériaux-Ruff

Befort

Matthes

Lannes

Micheletti

Mattéi

M. G.

Charron

Bloch

Kieffer

(1995). kappa-opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proceedings of the National Academy of Sciences of the United States of America, 92(15), 7006–7010.

93.

Skinner

M. K.

(2014). Environmental stress and epigenetic transgenerational inheritance. BMC Medicine, 12(1), 153.

94.

Slotkin

T. A.

(2008). If nicotine is a developmental neurotoxicant in animal studies, dare we recommend nicotine replacement therapy in pregnant women and adolescents? Neurotoxicology and Teratology, 30, 1–19.

95.

Spencer

T. J.

Bhide

Zhu

Faraone

S. V.

Fitzgerald

Yule

A. M.

Uchida

Spencer

A. E.

Hall

A. M.

Koster

A. J.

Biederman

(2018). Opiate antagonists do not interfere with the clinical benefits of stimulants in ADHD: A double-blind, placebo-controlled trial of the mixed opioid receptor antagonist naltrexone. The Journal of Clinical Psychiatry, 79(1), 16m11012.

96.

Spencer

T. J.

Bhide

Zhu

Faraone

S. V.

Fitzgerald

Yule

A. M.

Uchida

Spencer

A. E.

Hall

A. M.

Koster

A. J.

Feinberg

Kassabian

Storch

Biederman

(2018). The mixed opioid receptor antagonist naltrexone mitigates stimulant-induced euphoria: A double-blind, placebo-controlled trial of naltrexone. The Journal of Clinical Psychiatry, 79(2), 17m11609.

97.

Spencer

T. J.

Biederman

E. Ciccone

Madras

B. K.

Dougherty

D. D.

Bonab

A. A.

Livni

Parasrampuria

D. A.

Fischman

A. J.

(2006). PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. American Journal of Psychiatry, 163(3), 387–395.

98.

Swanson

J. M.

Volkow

N. D.

(2002). Pharmacokinetic and pharmacodynamic properties of stimulants: Implications for the design of new treatments for ADHD. Behavioural Brain Research, 130(1-2), 73–78.

99.

Teter

C. J.

McCabe

S. E.

LaGrange

Cranford

J. A.

Boyd

C. J.

(2006). Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy, 26(10), 1501–1510.

100.

Tong

V. T.

Dietz

P. M.

Farr

S. L.

D’Angelo

D. V.

England

L. J.

(2013). Estimates of smoking before and during pregnancy, and smoking cessation during pregnancy: Comparing two population-based data sources. Public Health Reports, 128(3), 179–188.

101.

Tong

V. T.

Dietz

P. M.

Morrow

D’Angelo

D. V.

Farr

S. L.

Rockhill

K. M.

England

L. J.

; Centers for Disease Control and Prevention (CDC). (2013). Trends in smoking before, during, and after pregnancy—Pregnancy risk assessment monitoring system, United States, 40 sites, 2000-2010. MMWR. Surveillance Summaries, 62(6), 1–19.

102.

Trigo

J. M.

Martin-García

Berrendero

Robledo

Maldonado

(2010). The endogenous opioid system: A common substrate in drug addiction. Drug and Alcohol Dependence, 108(3), 183–194.

103.

US-DHSS. (2016). E-cigarette use among youth and young adults. A report of the Surgeon General. In C. f. D. C. a. P. U.S. Department of Health and Human Services, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health (Ed.).

104.

Vaglenova

Birru

Pandiella

N. M.

Breese

C. R.

(2004). An assessment of the long-term developmental and behavioral teratogenicity of prenatal nicotine exposure. Behavioural Brain Research, 150(1-2), 159–170.

105.

Vassoler

F. M.

Byrnes

E. M.

Pierce

R. C.

(2014). The impact of exposure to addictive drugs on future generations: Physiological and behavioral effects. Neuropharmacology, 76, 269–275.

106.

Volkow

N. D.

Wang

G. J.

Fowler

J. S.

Ding

Y. S.

(2005). Imaging the effects of methylphenidate on brain dopamine: New model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biological Psychiatry, 57(11), 1410–1415.

107.

Wang

Liu

Gao

Yan

Rehan

V. K.

(2022). Perinatal exposure to nicotine alters sperm RNA profiles in rats. Frontiers in Endocrinology, 13, 893863.

108.

Werling

L. L.

Brown

S. R.

Cox

B. M.

(1987). Opioid receptor regulation of the release of norepinephrine in brain. Neuropharmacology, 26(7B), 987–996.

109.

Whittington

J. R.

Simmons

P. M.

Phillips

A. M.

Gammill

S. K.

Cen

Magann

E. F.

Cardenas

V. M.

(2018). The use of electronic cigarettes in pregnancy: A review of the literature. Obstetrical & Gynecological Survey, 73(9), 544–549.

110.

Wickström

(2007). Effects of nicotine during pregnancy: human and experimental evidence. Current Neuropharmacology, 5(3), 213–222.

111.

Wilens

T. E.

McBurnett

Turnbow

Rugino

White

Youcha

(2017). Morning and evening effects of guanfacine extended release adjunctive to psychostimulants in pediatric ADHD. Journal of Attention Disorders, 21(2), 110–119.

112.

Strathearn

Liu

Yang

Bao

(2018). Twenty-year trends in diagnosed attention-deficit/hyperactivity disorder among US children and adolescents, 1997-2016. JAMA Network Open, 1(4), e181471.

113.

Zhang

Wang

Tong

Sun

Zhang

(2013). Smoking, heart rate, and ischemic stroke: A population-based prospective cohort study among Inner Mongolians in China. Stroke, 44(9), 2457–2461.

114.

Yasuda

Raynor

Kong

Breder

C. D.

Takeda

Reisine

Bell

G. I.

(1993). Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proceedings of the National Academy of Sciences of the United States of America, 90(14), 6736–6740.

115.

Yohn

N. L.

Bartolomei

M. S.

Blendy

J. A.

(2015). Multigenerational and transgenerational inheritance of drug exposure: The effects of alcohol, opiates, cocaine, marijuana, and nicotine. Progress in Biophysics and Molecular Biology, 118(1-2), 21–33.

116.

Zeid

Goldberg

L. R.

Seemiller

L. R.

Mooney-Leber

Smith

P. B.

Gould

T. J.

(2021). Multigenerational nicotine exposure affects offspring nicotine metabolism, nicotine-induced hypothermia, and basal corticosterone in a sex-dependent manner. Neurotoxicology and Teratology, 85, 106972.

117.

Zeid

Gould

T. J.

(2023). Chronic nicotine exposure alters sperm small RNA content in C57BL/6J mouse model. Developmental Psychobiology, 65(2), e22367.

118.

Zhang

Levenson

C. W.

Salazar

V. C.

Biederman

Zafonte

Bhide

P. G.

(2022). Repetitive mild traumatic brain injury in an awake, unanesthetized mouse model of perinatal nicotine exposure produces transient novelty-seeking and depression-like behaviors. Journal of Neurotrauma, 39, 954–963.

119.

Zhang

Levenson

C. W.

Salazar

V. C.

McCarthy

D. M.

Biederman

Zafonte

Bhide

P. G.

(2021). Repetitive mild traumatic brain injury in a perinatal nicotine exposure mouse model of attention deficit hyperactivity disorder. Developmental Neuroscience, 43(1), 63–72.

120.

Zhang

McCarthy

D. M.

Eskow Jaunarajs

K. L.

Biederman

Spencer

T. J.

Bhide

P. G.

(2021). Frontal cortical monoamine release, attention, and working memory in a perinatal nicotine exposure mouse model following kappa opioid receptor antagonism. Cerebral Cortex, 31(1), 483–496.

121.

Zhang

Spencer

T. J.

Biederman

Bhide

P. G.

(2018). Attention and working memory deficits in a perinatal nicotine exposure mouse model. PLoS One, 13(5), e0198064.

122.

Zhang

Dai

Cao

Wang

Qiao

(2020). Paternal nicotine exposure induces hyperactivity in next-generation via down-regulating the expression of DAT. Toxicology, 431, 152367.

123.

Zhu

Fan

McCarthy

D. M.

Zhang

Cannon

E. N.

Spencer

T. J.

Biederman

Bhide

P. G.

(2017). A prenatal nicotine exposure mouse model of methylphenidate responsive ADHD-associated cognitive phenotypes. International Journal of Developmental Neuroscience, 58, 26–34.

124.

Zhu

Lee

K. P.

Spencer

T. J.

Biederman

Bhide

P. G.

(2014). Transgenerational transmission of hyperactivity in a mouse model of ADHD. The Journal of Neuroscience, 34(8), 2768–2773.

125.

Zhu

Spencer

T. J.

Liu-Chen

L. Y.

Biederman

Bhide

P. G.

(2011). Methylphenidate and μ opioid receptor interactions: A pharmacological target for prevention of stimulant abuse. Neuropharmacology, 61(1-2), 283–292.

126.

Zhu

Zhang

Spencer

T. J.

Biederman

Bhide

P. G.

(2012). Prenatal nicotine exposure mouse model showing hyperactivity, reduced cingulate cortex volume, reduced dopamine turnover, and responsiveness to oral methylphenidate treatment. The Journal of Neuroscience, 32(27), 9410–9418.

Preclinical Models of Attention Deficit Hyperactivity Disorder: Neurobiology,Drug Discovery,and Beyond

Abstract

Objective:

Method:

Results:

Conclusion:

Keywords

Get full access to this article

References